Back to News
Market Impact: 0.42
AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
AstraZeneca said its Phase III SERENA-4 trial of Etcamah (camizestrant) plus palbociclib failed to meet its primary progression-free-survival endpoint in first-line advanced ER-positive breast cancer. The trial setback is negative for the oncology pipeline and could reduce expectations for camizestrant’s commercial opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.62
Ticker Sentiment
AZN-0.82
More News
- Why GM and Hilton are ditching the NYSE for Nasdaq
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns